Q-omics provides the consensus-scored LARP6 profile across patient tissues and cancer cell-line models. LARP6 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, LARP6 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, LARP6 RNA expression shows 18,481 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight MESO, HNSC, and THYM as cancer lineages where LARP6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LARP6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LARP6 survival associations across molecular data types. LARP6 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (6) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LARP6 RNA expression–survival associations across cancer types. High LARP6 expression shows unfavorable associations in MESO, LUAD and STAD, but favorable associations in UCEC, THCA and SCLC. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for LARP6 RNA expression.
This table summarizes LARP6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 3. The strongest signals are observed in HNSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for LARP6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LARP6 shows lower tumor expression in THCA, KICH and BRCA and higher tumor expression in HNSC, LUSC and CHOL. The HNSC box plot shows higher LARP6 RNA expression in tumor versus normal tissue (log2 FC = +1.033, t-test p < 0.001).
This table shows molecular features associated with LARP6 in patient tissues and cancer cell lines. In patient samples, LARP6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, LARP6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in PANCREAS, while CRISPR and shRNA rows add functional-dependency signals in CNS and BONE.
